Combination therapy of losartan plus hydrochlorothiazide versus any angiotensin II blocker plus any calcium antagonist: effects on blood pressure and cardiac functio
Not Applicable
Completed
- Conditions
- Essential hypertension
- Registration Number
- JPRN-UMIN000012487
- Lead Sponsor
- Department of Cardiology, Osaka Medical College
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 26
Inclusion Criteria
Not provided
Exclusion Criteria
(1) ischemic heart disease (2) ischemic celebrovascular disease (3) serum creatinine >1.5 mg/dl and more(4) HbA1c <8.0 mg/dl and more (5) not tolerated to a new drug (6) patients already given high dose therapy of angiotensin II blocker
Study & Design
- Study Type
- Interventional,observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie losartan's antihypertensive effects compared to other angiotensin II blockers?
How does the losartan plus hydrochlorothiazide combination compare to standard angiotensin II blocker and calcium antagonist regimens in essential hypertension management?
Are there specific biomarkers that can predict patient response to losartan-based combination therapies in essential hypertension?
What are the potential adverse events associated with losartan plus hydrochlorothiazide compared to other antihypertensive combinations?
How do angiotensin II blockers and calcium antagonists synergize in blood pressure control and cardiac function improvement?